View More Recent Stories
-
APLT FRAUD NEWS: Applied Therapeutics, Inc. Investors are Notified of the February 18 Deadline in the Securities Fraud Class Action and are Urged to Contact BFA Law
-
William Blair Downgrades Applied Therapeutics (APLT) to Market Perform
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Purchasers to Secure Counsel Before Important Deadline in Securities Class Action - APLT
-
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Applied Therapeutics, Inc. Purchasers to Secure Counsel Before Important Deadline in Securities Class Action - APLT
-
APLT COURT NOTICE: BFA Law Alerts Applied Therapeutics, Inc. Investors a Securities Fraud Class Action Has Been Filed with a February 18 Court Deadline
-
ROSEN, GLOBALLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Applied Therapeutics, Inc. Purchasers to Secure Counsel Before Important Deadline in Securities Class Action - APLT
-
APLT INVESTOR NOTICE: Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Applied Therapeutics (APLT) PT Lowered to $1.50 at RBC Capital Following FDA's Warning Letter
-
Applied Therapeutics Inc. (APLT) Appoints John H. Johnson as Executive Chairman
-
APLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
APLT ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Applied Therapeutics, Inc. Investors
-
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Applied Therapeutics, Inc. (APLT)
-
Applied Therapeutics (APLT) PT Lowered to $5 at Baird
-
Applied Therapeutics (APLT) PT Lowered to $5 at Baird
-
Applied Therapeutics Inc. (APLT) call put ratio 1 call to 1.4 puts into receiving CRL from FDA on NDA for govorestat
-
RBC Capital Downgrades Applied Therapeutics (APLT) to Sector Perform
-
Applied Therapeutics (APLT) Receives CRL from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia
-
Applied Therapeutics Inc. (APLT) Halted, News Pending
-
Leerink Partners Reiterates Outperform Rating on Applied Therapeutics (APLT)
-
Applied Therapeutics Inc. (APLT) 6800 contracts of January 2.5 puts trade
-
Baird Reiterates Outperform Rating on Applied Therapeutics (APLT)
-
Applied Therapeutics Inc. (APLT) October 7.5, October 10 and January 12.50 calls active
-
Applied Therapeutics (APLT) Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia
-
William Blair Starts Applied Therapeutics (APLT) at Outperform
-
RBC Capital Reiterates Outperform Rating on Applied Therapeutics (APLT)
-
2Q24 U.S. biotech earnings preview

